Stay updated on Nivolumab vs. Everolimus in RCC: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.

Latest updates to the Nivolumab vs. Everolimus in RCC: Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThis updates the displayed ClinicalTrials.gov site revision/version label from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check20 days agoChange DetectedAdded collaborator Ono Pharmaceutical Co., Ltd.; removed Ono Pharmaceutical Co. Ltd. Revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedThe page now shows Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded Revision: v3.4.2 and removed the Notice about lapse in government funding and the previous Revision: v3.4.1.SummaryDifference0.2%

- Check91 days agoChange DetectedAdded a government funding lapse notice affecting site operations and a Lancet Oncology CheckMate 025 reference; removed the Lancet Oncology Erratum citation for that article (revision: v3.4.0).SummaryDifference0.2%

Stay in the know with updates to Nivolumab vs. Everolimus in RCC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.